Mabion (WAR:MAB) Valuation Rank


WAR:MAB Mabion SA WAR:MAB
29 GF Score
Price zł7.40
GF Value zł2.10
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Mabion Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Mabion Valuation Rank Related Terms

WAR:MAB
29GF Score
Mabion SA WAR:MAB
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mabion (WAR:MAB) Overvalued in 2026?

Based on GuruFocus' analysis, Mabion stock appears to be overvalued. The current stock price of zł7.40 is trading 252.4% above its estimated GF Value™ of zł2.10. GuruFocus considers Mabion to be Significantly Overvalued.

Key valuation signals for WAR:MAB:

  • Valuation Rank:
  • GF Value™: zł2.10 vs. price of zł7.40 (252.4% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the WAR:MAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mabion Business Description

Other Exchanges 272:Germany
Address ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
29GF Score

Get the complete analysis for WAR:MAB

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.40
Price
zł2.10
GF Value